Connect Biopharma Holdings Stock Market Value
| CNTB Stock | USD 0.86 0.01 1.18% |
| Symbol | Connect |
Connect Biopharma Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Connect Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Connect Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Connect Biopharma.
| 12/15/2024 |
| 03/15/2025 |
If you would invest 0.00 in Connect Biopharma on December 15, 2024 and sell it all today you would earn a total of 0.00 from holding Connect Biopharma Holdings or generate 0.0% return on investment in Connect Biopharma over 90 days. Connect Biopharma is related to or competes with Merck, Pfizer, Eli Lilly, Bristol Myers, Johnson Johnson, Amgen, and Gilead Sciences. Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development... More
Connect Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Connect Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Connect Biopharma Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 29.84 | |||
| Value At Risk | (7.07) | |||
| Potential Upside | 7.89 |
Connect Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Connect Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Connect Biopharma's standard deviation. In reality, there are many statistical measures that can use Connect Biopharma historical prices to predict the future Connect Biopharma's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | 0.3907 | |||
| Treynor Ratio | (0.21) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Connect Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Connect Biopharma Backtested Returns
Connect Biopharma secures Sharpe Ratio (or Efficiency) of -0.0545, which signifies that the company had a -0.0545 % return per unit of risk over the last 3 months. Connect Biopharma Holdings exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Connect Biopharma's Standard Deviation of 4.99, mean deviation of 3.68, and Risk Adjusted Performance of (0.03) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.12, which signifies a somewhat significant risk relative to the market. Connect Biopharma returns are very sensitive to returns on the market. As the market goes up or down, Connect Biopharma is expected to follow. At this point, Connect Biopharma has a negative expected return of -0.27%. Please make sure to confirm Connect Biopharma's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Connect Biopharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.07 |
Virtually no predictability
Connect Biopharma Holdings has virtually no predictability. Overlapping area represents the amount of predictability between Connect Biopharma time series from 15th of December 2024 to 29th of January 2025 and 29th of January 2025 to 15th of March 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Connect Biopharma price movement. The serial correlation of 0.07 indicates that barely 7.0% of current Connect Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.07 | |
| Spearman Rank Test | 0.18 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Connect Biopharma lagged returns against current returns
Autocorrelation, which is Connect Biopharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Connect Biopharma's stock expected returns. We can calculate the autocorrelation of Connect Biopharma returns to help us make a trade decision. For example, suppose you find that Connect Biopharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Connect Biopharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Connect Biopharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Connect Biopharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Connect Biopharma stock over time.
Current vs Lagged Prices |
| Timeline |
Connect Biopharma Lagged Returns
When evaluating Connect Biopharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Connect Biopharma stock have on its future price. Connect Biopharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Connect Biopharma autocorrelation shows the relationship between Connect Biopharma stock current value and its past values and can show if there is a momentum factor associated with investing in Connect Biopharma Holdings.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Connect Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Connect Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Connect Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Connect Biopharma Holdings Stock:Check out Connect Biopharma Correlation, Connect Biopharma Volatility and Connect Biopharma Alpha and Beta module to complement your research on Connect Biopharma. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Connect Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.